Association of polymorphisms in prolylcarboxypeptidase and chymase genes with essential hypertension in the Chinese Han population

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 14, Issue 3, 2013, Pages 263-270

  Wu, Yanrui ^a,b   Yang, Hongju ^b   Yang, Benguan ^b   Yang, Ke ^b   Xiao, Chunjie ^b  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b YUNNAN UNIVERSITY   (China)

Author keywords

CMA1; Essential hypertension; haplotype; PRCP; tag SNPs

Indexed keywords

CHYMASE; PROLINE CARBOXYPEPTIDASE;

ADULT; ALLELE; ARTICLE; BODY MASS; CASE CONTROL STUDY; CHINESE; CHYMASE GENE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; DNA POLYMORPHISM; ESSENTIAL HYPERTENSION; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PROLYLCARBOXYPEPTIDASE GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE;

CMA1; ESSENTIAL HYPERTENSION; HAPLOTYPE; PRCP; TAG SNPS;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; CARBOXYPEPTIDASES; CASE-CONTROL STUDIES; CHYMASES; ETHNIC GROUPS; EXONS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; HYPERTENSION; INTRONS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84881182805     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320312448949     Document Type: Article

References (47)

1. Choh AC, Czerwinski SA, Lee M, et al. Quantitative genetic analysis of blood pressure reactivity to orthostatic tilt using principal components analysis. J Hum Hypertens. 2006 ; 20: 281-289
2. Luft FC.. Twins in cardiovascular genetic research. Hypertension. 2001 ; 37: 350-356
3. Grimm RH, Cohen JD, Smith WM, et al. Hypertension management in the Multiple Risk Factor Intervention Trial (MRFIT). Six-year intervention results for men in special intervention and usual care groups. Arch Intern Med. 1985 ; 145: 1191-1199
4. Domanski M, Mitchell G, Pfeffer M, et al. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 2002 ; 287: 2677-2683
5. Ying CQ, Wang YH, Wu ZL, et al. Association of the renin gene polymorphism, three angiotensinogen gene polymorphisms and the haplotypes with essential hypertension in the Mongolian population. Clin Exp Hypertens. 2010 ; 32: 293-300
6. Ji LD, Zhang LN, Shen P, et al. Association of angiotensinogen gene M235T and angiotensin-converting enzyme gene I/D polymorphisms with essential hypertension in Han Chinese population: a meta-analysis. J Hypertens. 2010 ; 28: 419-428
7. Fang YJ, Deng HB, Thomas GN, et al. Linkage of angiotensinogen gene polymorphisms with hypertension in a sibling study of Hong Kong Chinese. J Hypertens. 2010 ; 28: 1203-1209
8. Niu W, Qi Y, Hou S, et al. Haplotype-based association of the renin-angiotensin-aldosterone system genes polymorphisms with essential hypertension among Han Chinese: the Fangshan study. J Hypertens. 2009 ; 27: 1384-1391
9. Bae Y, Park C, Han J, et al. Interaction between GNB3 C825T and ACE I/D polymorphisms in essential hypertension in Koreans. J Hum Hypertens. 2007 ; 21: 159-166
10. Jiang X, Sheng H, Li J, et al. Association between renin-angiotensin system gene polymorphism and essential hypertension: a community-based study. J Hum Hypertens. 2009 ; 23: 176-181
11. Rajan S, Ramu P, Umamaheswaran G, et al. Association of aldosterone synthase (CYP11B2 C-344T) gene polymorphism & susceptibility to essential hypertension in a south Indian Tamil population. Indian J Med Res. 2010 ; 132: 379-385
12. Hlubocka Z, Jachymova M, Heller S, et al. Association of the -344T/C aldosterone synthase gene variant with essential hypertension. Physiol Res. 2008 ; 58: 785-792
13. Watson B, Nowak NJ, Myracle AD, et al. The human angiotensinase C gene (HUMPCP) maps to 11q14 within 700 kb of D11S901: a candidate gene for essential hypertension. Genomics. 1997 ; 44: 365-367
14. Shariat-Madar B, Kolte D, Verlangieri A, et al. Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment. Diabetes Metab Syndr Obes. 2010 ; 3: 67-78
15. Zhou C, Garcia-Calvo M, Pinto S, et al. Design and synthesis of prolylcarboxypeptidase (PrCP) inhibitors to validate PrCP as a potential target for obesity. J Med Chem. 2010 ; 53: 7251-7263
16. Adams GN, LaRusch GA, Stavrou E, et al. Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood. 2011 ; 117: 3929-3937
17. Mallela J, Yang J, Shariat-Madar Z. Prolylcarboxypeptidase: a cardioprotective enzyme. Int J Biochem Cell Biol. 2009 ; 41: 477-481
18. Shariat-Madar Z, Mahdi F, Schmaier AH. Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood. 2004 ; 103: 4554-4561
19. Shariat-Madar Z, Rahimy E, Mahdi F, et al. Overexpression of prolylcarboxypeptidase enhances plasma prekallikrein activation on Chinese hamster ovary cells. Am J Physiol Heart Circ Physiol. 2005 ; 289: H2697 - H2703
20. Doggrell SA, Wanstall JC. Vascular chymase: pathophysiological role and therapeutic potential of inhibition. Cardiovasc Res. 2004 ; 61: 653-662
21. Bacani C, Frishman WH. Chymase: a new pharmacologic target in cardiovascular disease. Cardiol Rev. 2006 ; 14: 187-193
22. Ihara M, Urata H, Kinoshita A, et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension. 1999 ; 33: 1399-1405
23. Nishimoto M, Takai S, Fukumoto H, et al. Increased local angiotensin II formation in aneurysmal aorta. Life Sci. 2002 ; 71: 2195-2205
24. Guo C, Ju H, Leung D, et al. A novel vascular smooth muscle chymase is upregulated in hypertensive rats. J Clin Invest. 2001 ; 107: 703-715
25. Levy D, DeStefano AL, Larson MG, et al. Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study. Hypertension. 2000 ; 36: 477-483
26. Garcia EA, Newhouse S, Caulfield MJ, et al. Genes and hypertension. Curr Pharm Des. 2003 ; 9: 1679-1689
27. Martin ER, Lai EH, Gilbert JR, et al. SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. Am J Hum Genet. 2000 ; 67: 383-394
28. Chu SL, Zhu DL, Xiong MM, et al. Linkage analysis of twelve candidate gene loci regulating water and sodium metabolism and membrane ion transport in essential hypertension. Hypertens Res. 2002 ; 25: 635-639
29. Nie SJ, Wen-ru T, Bi-feng C, et al. Haplotype-based case-control study of the human AGTR1 gene and essential hypertension in Han Chinese subjects. Clin Biochem. 2010 ; 43: 253-258
30. Gross-Bellard M, Oudet P, Chambon P. Isolation of high-molecular-weight DNA from mammalian cells. Eur J Biochem. 1973 ; 36: 32-38
31. Li Z, Zhang Z, He Z, et al. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res. 2009 ; 19: 519-523
32. Zhang K, Qin ZS, Liu JS, et al. Haplotype block partitioning and tag SNP selection using genotype data and their applications to association studies. Genome Res. 2004 ; 14: 908-916
33. Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit. 2005 ; 11: 194-205
34. Mento PF, Wilkes BM. Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension. 1987 ; 9: III42-48
35. Atkinson JB, Harlan CW, Harlan GC, Virmani R. The association of mast cells and atherosclerosis: a morphologic study of early atherosclerotic lesions in young people. Hum Pathol. 1994 ; 25: 154-159
36. Fukuda M, Ohkubo T, Katsuya T, et al. Association of a mast cell chymase gene variant with HDL cholesterol, but not with blood pressure in the Ohasama study. Hypertens Res. 2002 ; 25: 179-184
37. Ono K, Kokubo Y, Mannami T, Inamoto N, Shioji K, Iwai N. Heterozygous disruption of CMA1 does not affect blood pressure. J Hypertens. 2004 ; 22: 103-109
38. Chikhladze NM, Samedova Kh F, Sudomoina MA, et al. [Comparative genetic analysis of different forms of low-renin arterial hypertension]. Mol Biol (Mosk). 2008 ; 42: 588-598
39. Chung WK, Deng L, Carroll JS, et al. Polymorphism in the angiotensin II type 1 receptor (AGTR1) is associated with age at diagnosis in pulmonary arterial hypertension. J Heart Lung Transplant. 2009 ; 28: 373-379
40. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science. 2002 ; 296: 2225-2229
41. Patil N, Berno AJ, Hinds DA, et al. Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science. 2001 ; 294: 1719-1723
42. Zhang K, Qin Z, Chen T, et al. HapBlock: haplotype block partitioning and tag SNP selection software using a set of dynamic programming algorithms. Bioinformatics. 2005 ; 21: 131-134
43. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007 ; 449: 851-861
44. Wallingford N, Perroud B, Gao Q, et al. Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents. J Clin Invest. 2009 ; 119: 2291-2303
45. McCarthy JJ, Meyer J, Moliterno DJ, et al. Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients. Hum Genet. 2003 ; 114: 87-98
46. Wang L, Feng Y, Zhang Y, et al. Prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia. Am J Obstet Gynecol. 2006 ; 195: 162-171
47. Zhang Y, Hong XM, Xing HX, et al. E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients. Chin Med J (Engl). 2009 ; 122: 2461-2465